Reata Pharmaceuticals news

Reata Pharmaceuticals

Biogen is buying Reata Pharmaceuticals for $7.3 billion, or $172.5 per share. Closing of the transaction is expected to take place in Q4 2023.

Reata Pharmaceuticals

Reata Pharmaceuticals' GAAP loss for 3 months of 2022 was $73.842 million, up 9.5% from $67.455 million in the previous year. Revenue decreased 3.2% to $914,000 from $944,000 a year earlier.

Reata Pharmaceuticals

Reata Pharmaceuticals' GAAP loss for 2021 was $297.386 million, up 20% from $247.752 million in the previous year. Revenue increased 27.4% to $11.49 million from $9.019 million a year earlier.

Reata Pharmaceuticals

An FDA advisory committee has recommended against approval of Reata Pharmaceuticals' bardoxolone. The drug is being developed to treat patients with chronic kidney disease caused by Alport syndrome. The committee felt that the evidence presented did not show a slowing of progression of CKD in patients with Alport syndrome. The final decision rests with the F...

Reata Pharmaceuticals

Reata Pharmaceuticals' GAAP loss for 9M 2021 was $212.001 million, up 16.5% from $181.976 million in the previous year. Revenue increased 81.2% to $10.557 million from $5.827 million a year earlier.

Reata Pharmaceuticals

Reata Pharmaceuticals' GAAP loss for 6M 2021 was $140.155 million, up 20.3% from $116.52 million in the previous year. Revenues fell 28.5% to $3.166 million from $4.426 million a year earlier.

Reata Pharmaceuticals

Reata Pharmaceuticals' GAAP loss for three months 2021 was $67.455 million, up 37.8% from $48.939 million in the previous year. Revenue declined 30.2% to $0.944 million from $1.353 million a year earlier.

Reata Pharmaceuticals

Reata Pharmaceuticals' GAAP loss for 2020 was $247.752 million, down 14.6% from $290.17 million in the previous year. Revenues fell threefold to $9.019 million from $26.517 million a year earlier.

Reata Pharmaceuticals

The loss of Reata Pharmaceuticals under GAAP for 9 months of 2020 amounted to $181.976 million, an increase of 76.3% compared to $103.228 million in the previous year. Revenues decreased 4 times to $5,827 million against $23,846 million a year earlier.